阿奇霉素治疗需住院的慢阻肺急性加重:BACE随机对照试验
BACE多中心随机双盲安慰剂对照试验纳入301例因慢阻肺急性加重住院、吸烟史≥10包年且过去一年≥1次加重的患者,在入院48小时内随机给予3个月低剂量阿奇霉素或安慰剂。3个月内治疗失败率阿奇霉素组49%、安慰剂组60%(HR 0.73,95%CI 0.53-1.01,P=0.0526),停药6个月后临床获益消失。
要点
- 因慢阻肺急性加重住院患者早期加用3个月低剂量阿奇霉素,3个月内治疗失败率有降低趋势但未达统计学显著。
- 治疗强化和住院升级在阿奇霉素组显著低于安慰剂组,全因死亡率两组差异无统计学意义。
- 停用阿奇霉素6个月后临床获益消失,提示可能需要延长疗程以维持获益。
核心结论
- 对需要住院的感染性慢阻肺急性加重患者,3个月低剂量阿奇霉素可能显著降低最高风险期内的治疗失败率。
- 延长治疗似乎是维持临床获益所必需的。
研究设计与样本
- 研究者发起的多中心、随机、双盲、安慰剂对照试验。
- 纳入因慢阻肺急性加重住院、吸烟史≥10包年且过去一年有≥1次加重的患者,入院48小时内按1:1随机分组。
- 共随机301例,阿奇霉素组147例、安慰剂组154例。
- 研究药物为阿奇霉素500 mg/d×3 d后250 mg/2 d继续至3个月,叠加于全身糖皮质激素和抗生素的标准化急性治疗之上,随后随访6个月。
- 主要终点为意向治疗人群3个月内首次事件分析的治疗失败率,治疗失败定义为需强化全身糖皮质激素和/或抗生素、住院升级或因呼吸原因再入院、或全因死亡的复合终点。
主要发现
- 3个月内治疗失败率阿奇霉素组49%、安慰剂组60%(HR 0.73,95%CI 0.53-1.01,P=0.0526)。
- 3个月内治疗强化率阿奇霉素组47%、安慰剂组60%(P=0.0272)。
- 3个月内住院升级率阿奇霉素组13%、安慰剂组28%(P=0.0024)。
- 3个月内死亡率阿奇霉素组2%、安慰剂组4%(P=0.5075)。
- 停药6个月后临床获益消失。
临床怎么用
- 对因慢阻肺急性加重住院且符合入选标准(吸烟史≥10包年、过去一年≥1次加重)的患者,可考虑在标准化急性治疗基础上早期加用3个月低剂量阿奇霉素。
- 需注意3个月疗程结束后临床获益可能不维持,应评估是否需要延长治疗。
局限性
- 主要终点治疗失败率的差异未达到传统统计学显著性(P=0.0526)。
- 停药6个月后临床获益消失,长期疗效不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Azithromycin prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPDs); however, its value in the treatment of an AECOPD requiring hospitalization remains to be defined.Objectives: We investigated whether a 3-month intervention with low-dose azithromycin could decrease treatment failure (TF) when initiated at hospital admission and added to standard care.Methods: In an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial, patients who had been hospitalized for an AECOPD and had a smoking history of ≥10 pack-years and one or more exacerbations in the previous year were randomized (1:1) within 48 hours of hospital admission to azithromycin or placebo. The study drug (500 mg/d for 3 d) was administered on top of a standardized acute treatment of systemic corticosteroids and antibiotics, and subsequently continued for 3 months (250 mg/2 d). The patients were followed for 6 months thereafter. Time-to-first-event analyses evaluated the TF rate within 3 months as a novel primary endpoint in the intention-to-treat population, with TF defined as the composite of treatment intensification with systemic corticosteroids and/or antibiotics, a step-up in hospital care or readmission for respiratory reasons, or all-cause mortality.Measurements and Main Results: A total of 301 patients were randomized to azithromycin (n = 147) or placebo (n = 154). The TF rate within 3 months was 49% in the azithromycin group and 60% in the placebo group (hazard ratio, 0.73; 95% confidence interval, 0.53-1.01; P = 0.0526). Treatment intensification, step-up in hospital care, and mortality rates within 3 months were 47% versus 60% (P = 0.0272), 13% versus 28% (P = 0.0024), and 2% versus 4% (P = 0.5075) in the azithromycin and placebo groups, respectively. Clinical benefits were lost 6 months after withdrawal.Conclusions: Three months of azithromycin for an infectious AECOPD requiring hospitalization may significantly reduce TF during the highest-risk period. Prolonged treatment seems to be necessary to maintain clinical benefits.
引用
- Vermeersch K, Gabrovska M, Aumann J, et al. Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2019. PMID: 31046405. doi:10.1164/rccm.201901-0094OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。